Ballicules.com

Viloxazine

QELBREE

What it isNorepinephrine-reuptake inhibitor with serotonergic activity; ADHD.

Why this oneIt is a noncontrolled ADHD treatment with serotonergic activity that atomoxetine lacks.

What limits itStrong CYP1A2 inhibition can sharply raise clozapine or theophylline exposure; somnolence and suicidality also matter.

FDA-approved for

FDA label

BOXED WARNING Suicidal thoughts and behaviors in ADHD patients; monitor closely
FDA dosingPopulationStartTargetMax
ADHDpediatric 6-11y100 mg QDtitrate to response400 mg QD
ADHDpediatric 12-17y200 mg QDtitrate to response400 mg QD
ADHDadult200 mg QDtitrate to response600 mg QD

Titration Increase at weekly intervals (100 mg peds 6-11y; 200 mg peds 12-17y and adults)

Renal Severe (eGFR <30): start 100 mg QD, titrate weekly by 50-100 mg to max 200 mg QD

Hepatic Undefined

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy May cause maternal harm; discontinue when pregnancy is recognized unless benefit outweighs risk

Lactation Low transfer into breastmilk (relative infant dose ~1%)

⚠ BOXED WARNING

Cost, est. cash$300–$2,500/month

Generic entry2033 est.

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryNot assigned — PLLR-era drug

Defining liabilitySomnolence or activation, blood-pressure effects and suicidal-thinking warning in younger patients.

Mechanism of action: Viloxazine ballicule

Viloxazine ballicule: receptor binding, kinetics and half-life diagram

Open Viloxazine in the interactive console ↗

Memory aids: mascots and interaction avatars

Viloxazine QELBREE mascot mnemonic cartoon
“Vibrant locks Quell the breeze”
CYP1A2 inHibitor
Viloxazine CYP1A2 inhibitor avatar
CYP1A2 inhibitor (strong)

Open Viloxazine in the interactive console ↗